Skip to main content
Clinical Trials/NCT00245648
NCT00245648
Completed
Phase 3

Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial

NYU Langone Health1 site in 1 countryJune 2001

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Myocardial Infarction
Sponsor
NYU Langone Health
Locations
1
Primary Endpoint
Primary Outcome
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.

Detailed Description

The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO) V trial examined a large, contemporary cohort of women and men with ST elevation myocardial infarction (STEMI) treated with fibrinolytic therapy. The objective of the present study was to evaluate sex differences in presentation, management and outcome in GUSTO V.

Registry
clinicaltrials.gov
Start Date
June 2001
End Date
October 2007
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Harmony R. Reynolds

Assistant Professor

NYU Langone Health

Eligibility Criteria

Inclusion Criteria

  • inclusion into GUSTO V

Exclusion Criteria

  • lack of availability of data (database study)

Outcomes

Primary Outcomes

Primary Outcome

Time Frame: 30 days

All cause mortality at 30 days after randomization.

Secondary Outcomes

  • Secondary Outcomes(7 days)

Study Sites (1)

Loading locations...

Similar Trials